Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced

References

• Paulukonis ST, Eckman JR, Snyder AB, et al. Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep. 2016;131:367–375.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Sickle-cell disease and other haemoglobin disorders. In: WHO fact sheet 308. Geneva: World Health Organization; 2011.
   Google Scholar
• Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:e1001484.
   PubMed Web of Science ®Google Scholar
• Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol. 2000 May;1(151):839–845.
   Google Scholar
• Grosse SD, Schechter MS, Kulkarni R, et al. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123:407–412.
   PubMed Web of Science ®Google Scholar
• Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996 Aug 8;335:369–376.
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Fitzhugh CD, Weitzel R, et al. Nonmyeloablative hla-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312:48–56.
   PubMed Web of Science ®Google Scholar
• Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7:665–673.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129:1548–1556.
   PubMed Web of Science ®Google Scholar
• Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447–3452.
   PubMed Web of Science ®Google Scholar
• Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011;41:S398–405.
   PubMed Web of Science ®Google Scholar
• Nickel RS, Kamani NR. Ethical challenges in hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2018 Feb;24:219–227.
   PubMedGoogle Scholar
• Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99:811–820.
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Robin M, Ferry C, et al. Related myeloablative stem cell transplantation (SCT) to cure sickle cell anemia (SCA): update of French results. Blood. 2010;116:3518.
   Web of Science ®Google Scholar
• Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110:2749–2756.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Potschger U, Bergmann K, et al. Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:335–343.
   PubMed Web of Science ®Google Scholar
• Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002;140:348–354.
   PubMed Web of Science ®Google Scholar
• Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011 Jan;20(117):772–779.
   Google Scholar
• Bhatia M, Sheth S. Hematopoietic stem cell in sickle cell disease: patient selection and special considerations. J Blood Med. 2015;6:229–238.
   PubMed Web of Science ®Google Scholar
• Kassim AA, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017 Dec;10:259–266.
   PubMedGoogle Scholar
• Chakrabarti S, Bareford D. A survey on patient perception of reduced-intensity transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2007 Apr;39:447–451.
   PubMed Web of Science ®Google Scholar
• Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984 Sep 20;311:780–783.
   PubMed Web of Science ®Google Scholar
• Vermylen C, Cornu G, Ferster A, et al. Bone marrow transplantation in sickle cell disease: the Belgian experience. Bone Marrow Transplant. 1993;12(Suppl 1):116–117.
   PubMedGoogle Scholar
• Bernaudin F, Souillet G, Vannier JP, et al. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO Bone Marrow Transplant. 1993;12(Suppl 1):118–121.
   PubMedGoogle Scholar
• Lucarelli G, Isgrò A, Sodani P, et al. Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Bone Marrow Transplant. 2014;49:1376–1381.
   PubMed Web of Science ®Google Scholar
• Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014;49:913–920.
   PubMed Web of Science ®Google Scholar
• Dedeken L, Lê PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol. 2014;165:402–408.
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007 Oct 1;110:2749–2756.
   PubMed Web of Science ®Google Scholar
• McPherson ME, Hutcherson D, Olson E, et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 2011;46:27–33.
   PubMed Web of Science ®Google Scholar
• Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998 Jul;22:1–6.
   PubMed Web of Science ®Google Scholar
• Panepinto JA, Walters MC, Carreras J, et al. Non-malignant marrow disorders working committee, center for international blood and marrow transplant research. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137:479–485.
   PubMed Web of Science ®Google Scholar
• Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000 Mar;15(95):1918–1924.
   Google Scholar
• Brachet C, Azzi N, Demulder A, et al. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation’s outcome. Bone Marrow Transplant. 2004;33:799–803.
   PubMed Web of Science ®Google Scholar
• Walters MC, Sullivan KM, Bernaudin F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood. 1995 Feb;15(85):879–884.
   Google Scholar
• Horan JT, Liesveld JL, Fenton P, et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant. 2005;35:171–177.
   PubMed Web of Science ®Google Scholar
• Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9:519–528.
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Duerst R, Tse W, et al. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004;364:156–162.
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009 Dec 10;361:2309–2317.
   PubMed Web of Science ®Google Scholar
• Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol. 1999;162:2775–2784.
   PubMed Web of Science ®Google Scholar
• Powell JD, Fitzhugh C, Kang EM, et al. Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation. 2005;80:1541–1545.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078.
   PubMed Web of Science ®Google Scholar
• Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant. 2016;22:441–448.
   PubMed Web of Science ®Google Scholar
• Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14:1270–1278.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Grossman WJ, DiPersio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35:345–352.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Lawitschka A, Fritsch G, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol. 2013;90:308–312.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Rocha V, Gluckman E, et al. Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant. 2008;14:44–53.
   PubMed Web of Science ®Google Scholar
• Switzer GE, Bruce JG, Myaskovsky L, et al. Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood. 2013 Feb;21(121):1469–1476.
   Google Scholar
• Krishnamurti L, Abel S, Maiers M, et al. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant. 2003;31:547–550.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Kabbara N, Ruggeri A, et al. Eurocord and European Blood and Marrow Transplantation (EBMT) group. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013 Aug 8;122:1072–1078.
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A. 1989;86:3828–3832.
   PubMed Web of Science ®Google Scholar
• Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122:491–498.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003 Mar 15;101:2137–2143.
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant. 2007;11:641–644.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan K, Bhatia M, Geyer MB, et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant. 2013 Apr;19:676–677.
   PubMed Web of Science ®Google Scholar
• Eurocord Registry; Center for International Blood and Marrow Transplant Research; New York Blood Center, Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011 Sep;17:1375–1382.
   PubMed Web of Science ®Google Scholar
• Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18:1265–1272.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Eapen M, Panepinto JA, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128:2561–2567.
   PubMed Web of Science ®Google Scholar
• Krishnamurti L, Sullivan KM, Kamani NR, et al. Results of a multicenter pilot investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). Blood. 2015;126:543.
   Web of Science ®Google Scholar
• Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010;17:493–499.
   PubMed Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638–647.
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285–4291.
   PubMed Web of Science ®Google Scholar
• Dhedin N, Fuente J, Bernaudin F, et al. Haploidentical bone marrow transplant with post-transplant Cytoxan plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international multicenter learning collaborative. Blood. 2016;128:1233.
   Web of Science ®Google Scholar
• Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013 May;19:820–830.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Angelucci E, Arnold SD, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:552–561.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Gaziev J, Angelucci E, et al. Late effects screening guidelines after Hematopoietic Cell Transplantation (HCT) for hemoglobinopathy: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2018 Apr10. pii: S1083–8791(18)30182–4. DOI:10.1016/j.bbmt.2018.04.002. [Epub ahead of print]
   Google Scholar
• Walters MC, Hardy K, Edwards S, et al. Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263–272.
   PubMed Web of Science ®Google Scholar
• Woodard P, Helton KJ, Khan RB, et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol. 2005;129:550–552.
   PubMed Web of Science ®Google Scholar
• Padovan CS, Yousry TA, Schleuning M, et al. Neurological and neuroradiological findings in long-term survivors of allogeneic bone marrow transplantation. Ann Neurol. 1998;43:627–633.
   PubMed Web of Science ®Google Scholar
• Bodas P, Rotz S. Cerebral vascular abnormalities in pediatric patients with sickle cell disease after hematopoietic cell transplant. J Pediatr Hematol Oncol. 2014 Apr;36:190–193.
   PubMed Web of Science ®Google Scholar
• Ferster A, Bujan W, Corazza F, et al. Bone marrow transplantation corrects the splenic reticuloendothelial dysfunction in sickle cell anemia. Blood. 1993 Feb;15(81):1102–1105.
   Google Scholar
• Bhatia M, Kolva E, Cimini L, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015;21:666–672.
   PubMed Web of Science ®Google Scholar
• Darbari DS, Liljencrantz J, Ikechi A, et al. Pain and opioid use after reversal of sickle cell disease following HLA‐matched sibling haematopoietic stem cell transplant. Br J Haematol. 2018. DOI:10.1111/bjh.15169
   Google Scholar
• Smith-Whitley K. Reproductive issues in sickle cell disease. Hematol Am Soc Hematol Educ Program. 2014 Dec;5(2014):418–424.
   Google Scholar
• Brachet C, Heinrichs C, Tenoutasse S, et al. Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2007;29:445–450.
   PubMed Web of Science ®Google Scholar
• Pfeifer S, Goldberg J, Lobo R, et al. Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013 Nov;100:1214–1223.
   PubMedGoogle Scholar
• Santarone S, Natale A, Olioso P, et al. Pregnancy outcome following hematopoietic cell transplantation for thalassemia major. Bone Marrow Transplant. 2017;52:388–393.
   PubMedGoogle Scholar
• Madden LM, Hayashi RJ, Chan KW, et al. Long-term follow-up after reduced-intensity conditioning and stem cell transplantation for childhood nonmalignant disorders. Biol Blood Marrow Transplant. 2016;22:1467–1472.
   PubMedGoogle Scholar
• Rahal I, Galambrun C, Bertrand Y, et al. Late effects after hematopoietic stem cell transplantation for beta-thalassemia major: the French national experience. Haematologica. 2018 Mar 29. pii: haematol.2017.183467. DOI:10.3324/haematol.2017.183467. [Epub ahead of print]
   PubMedGoogle Scholar
• Gharwan H, Neary NM, Link M, et al. Successful fertility restoration after allogeneic hematopoietic stem cell transplantation. Endocr Pract. 2014;20:e157–61.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl JMed. 1990 Aug;30(323):570–578.
   Google Scholar
• Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002 Apr;18(346):1185–1193.
   Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000 Apr 28;288:669–672.
   PubMed Web of Science ®Google Scholar
• Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010 Nov 11;363:1918–1927.
   PubMed Web of Science ®Google Scholar
• Goebel WS, Dinauer MC. Gene therapy for chronic granulomatous disease. Acta Haematol. 2003;110:86–92.
   PubMed Web of Science ®Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401–409.
   PubMed Web of Science ®Google Scholar
• Fitzhugh CD, Cordes S, Taylor T, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017 Oct 26;130:1946–1948.
   PubMed Web of Science ®Google Scholar
• Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature. 1988 Jan;7(331):35–41.
   Google Scholar
• May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassemiaassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000 Jul;6(406):82–86.
   Google Scholar
• May C, Rivella S, Chadburn A, et al. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood. 2002 Mar;15(99):1902–1908.
   Google Scholar
• Imren S, Payen E, Westerman KA, et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002 Oct;29(99):14380–14385.
   Google Scholar
• Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001 Dec;14(294):2368–2371.
   Google Scholar
• Levasseur DN, Ryan TM, Pawlik KM, et al. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood. 2003 Dec;15(102):4312–4319.
   Google Scholar
• Thompson A, Rasko J, Hongeng S, et al. Initial Results from the Northstar Study (HGB-204): a phase 1/2 study of gene therapy for β-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral βΑ-T87Q -globin vector (lentiglobin BB305 drug product). Blood. 2014;124:549.
   Google Scholar
• Walters M, Rasko J, Hongeng S, et al. Update of Results from the Northstar Study (HGB-204): a phase 1/2 study of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex-vivo with a lentiviral beta AT87Q-globin vector (lentiglobin BB305 drug product). Blood. 2015;126:201.
   Google Scholar
• Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018 Apr 19;378:1479–1493.
   PubMed Web of Science ®Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017 Mar 2;376:848–855.
   PubMed Web of Science ®Google Scholar
• Cavazzana M, Hacein-Bey-Abina S, Payen E, et al. Longer term follow-up on the first patients with severe hemoglobinopathies treated with lentiglobin gene therapy. Blood. 2017;130:4609.
   Google Scholar
• Kanter J, Walters MC, Hsieh M, et al. Interim results from a phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. Blood. 2017;130:527.
   PubMed Web of Science ®Google Scholar
• Demuynck H, Pettengell R, de Campos E, et al. The capacity of peripheral blood stem cells mobilised with chemotherapy plus G-CSF to repopulate irradiated marrow stroma in vitro is similar to that of bone marrow. Eur J Cancer. 1992;28:381–386.
   PubMed Web of Science ®Google Scholar
• Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood. 1993 Apr;15(81):2031–2035.
   Google Scholar
• Uchida N, Bonifacino A, Krouse AE, et al. Acclerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. Exp Hematol. 2011;39:795–805.
   PubMed Web of Science ®Google Scholar
• Choi E, Branch C, Cui MH, et al. No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice. Blood Cells Mol Dis. 2016;57:67–70.
   PubMed Web of Science ®Google Scholar
• Uchida N, Fujita A, Hsieh MM, et al. Bone marrow as a hematopoietic stem cell source for gene therapy in sickle cell disease: evidence from rhesus and SCD patients. Hum Gene Ther Clin Dev. 2017;28:136–144.
   PubMed Web of Science ®Google Scholar
• Tisdale JF, Pierciey FJ, Kamble R, et al. Successful plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease. Blood. 2017;130:990.
   Web of Science ®Google Scholar
• Leonard A, Bonifacino A, Vm D, et al. Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery compared to normal volunteer bone marrow. Blood. 2017;130:966.
   Web of Science ®Google Scholar
• Hoban MD, Lumaquin D, Kuo CY, et al. CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol Ther. 2016;24:1561–1569.
   PubMed Web of Science ®Google Scholar
• Obama B. United States health care reform: progress to date and next steps. JAMA. 2016;316:525–532.
   PubMed Web of Science ®Google Scholar
• Wendy Darlington W, Watson SP, Henderson TO, et al. The affordable care act improves healthcare access and utilization among young adults with sickle cell disease. Blood. 2016;128:4747.
   Web of Science ®Google Scholar
• Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999–2009). Pediatr Blood Cancer. 2013 Sep;60:1482–1486.
   PubMed Web of Science ®Google Scholar
• Ballas SK. The cost of health care for patients with sickle cell disease. Am J Hematol. 2009 Jun;84:320–322.
   PubMed Web of Science ®Google Scholar
• Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84:323–327.
   PubMed Web of Science ®Google Scholar
• Jiang HJ, Weiss AJ, Barrett ML, et al. Characteristics of Hospital Stays for Super-Utilizers by Payer, 2012: statistical Brief #190. 2015 May. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb. Available from: https://www.ncbi.nlm.nih.gov/books/NBK310271/
   Google Scholar
• Arnold SD, Brazauskas R, He N, et al. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica. 2017;102:1823–1832.
   PubMed Web of Science ®Google Scholar
• Saenz C, Tisdale JF. Assessing costs, benefits, and risks in chronic disease: taking the long view. Biol Blood Marrow Transplant. 2015 Jul;21:1149–1150.
   PubMedGoogle Scholar
• Marrazzo J, Leschly N, Daniel G, et al. Advancing gene therapies and curative health care through value-based payment reform. Health Affairs Blog. 2017 Oct 30.
   Google Scholar
• Lê PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer. 2015;62:1956–1961.
   PubMed Web of Science ®Google Scholar
• Nietert PJ, Abboud MR, Silverstein MD, et al. Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood. 2000;95:3057–3064.
   PubMed Web of Science ®Google Scholar
• Adam SS, Flahiff CM, Kamble S, et al. Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Adv. 2017 Oct;12(1):1983–1992.
   Google Scholar